FCE-28068

Known as: FCE28068 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Intravenously (i.v.) administered nanomedicines have the potential for tumour targeting due to the enhanced permeability and… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled… (More)
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
Review
2009
Review
2009
This paper reviews an early clinical experience with anthracycline (epirubicin; Epi or doxorubicin; Dox) containing an N-(2… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2007
2007
Recently we have described an HPMA copolymer conjugate carrying both the aromatase inhibitor aminoglutethimide (AGM) and… (More)
Is this relevant?
Review
2005
Review
2005
The last decade has seen successful clinical application of polymer-protein conjugates (e.g. Oncaspar, Neulasta) and promising… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2001
2001
There are now at least seven polymer-drug conjugates that have entered phase I/II clinical trial as anticancer agents. These… (More)
Is this relevant?